Fig. 5.
In vivo antitumor effects of OBP-702 and OBP-301 against GR PAN02 tumors. A GR PAN02 cells (4 × 106 cells/site) were inoculated into the flanks of C57BL/6J mice on day − 28. OBP-301 (red arrows) or OBP-702 (blue arrows) was injected intratumorally at 1 × 108 PFUs on days 0, 2, and 4. One experiment has been performed. B Photographs of tumors in the control, OBP-301, and OBP-702 groups. C Tumor growth curves for non-treated control (black line), OBP-301-treated (red line), and OBP-702-treated (blue line) mice. D Representative photographs of immunohistochemical staining of CD8+ T cells and Gr1+ MDSCs in each group. Scale bars, 100 µm. The number of CD8+ T cells and percent area of Gr1+ MDSCs were calculated from five different randomly selected fields. E Representative data of flow cytometric analysis of CD8, CD4, CD11b, and Gr1 in each group. The percentages of CD8+ T cells and CD4+ T cells among CD3+ cells and the percentage of CD11b+Gr1+ MDSCs among CD45+ cells are shown. Data are expressed as mean ± SD (n = 7 in each group; *P < 0.05; **P < 0.01; ***P < 0.001)